These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 18999936)

  • 1. High-dose intensity pulse interleukin-2 with famotidine has activity in metastatic melanoma.
    Quan WD; Walker PR; Picton M; Quan FM; King LA; Tyre C; Liles DK
    Cancer Biother Radiopharm; 2008 Oct; 23(5):641-6. PubMed ID: 18999936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer.
    Quan WD; Quan FM
    Cancer Biother Radiopharm; 2009 Apr; 24(2):181-3. PubMed ID: 19409039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient intravenous interleukin-2 with famotidine has activity in metastatic melanoma.
    Quan WD; Quan FM; Perez M; Johnson E
    Cancer Biother Radiopharm; 2012 Sep; 27(7):442-5. PubMed ID: 22731929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma.
    Quan W; Knupp C; Quan F; Walker P
    Cancer Biother Radiopharm; 2010 Apr; 25(2):179-83. PubMed ID: 20423231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
    Quan WD; Walker PR; Quan FM; Ramirez M; Elsamaloty HM; Ghai V; Vinogradov M; Liles DK
    Cancer Biother Radiopharm; 2006 Oct; 21(5):437-42. PubMed ID: 17105418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous infusion interleukin-2 and intravenous famotidine in metastatic melanoma.
    Quan WD; Milligan KS; Quan FM; Cuenca RE; Khan N; Liles DK; Walker PR
    Cancer Biother Radiopharm; 2006 Dec; 21(6):607-12. PubMed ID: 17257076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
    Quan WD; Quan FM; King LA; Walker PR
    Cancer Biother Radiopharm; 2008 Feb; 23(1):108-13. PubMed ID: 18298334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma.
    Quan WD; Quan FM
    Cancer Biother Radiopharm; 2009 Feb; 24(1):1-6. PubMed ID: 19243244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of outpatient intravenous interleukin-2 and famotidine in metastatic clear cell kidney cancer.
    Quan WD; Quan FM
    Cancer Biother Radiopharm; 2014 Mar; 29(2):58-61. PubMed ID: 24251758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma.
    Quan W; Ramirez M; Taylor WC; Vinogradov M; Khan N; Jackson S
    Cancer Biother Radiopharm; 2004 Dec; 19(6):770-5. PubMed ID: 15665626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over.
    Quan W; Ramirez M; Taylor C; Quan F; Vinogradov M; Walker P
    Cancer Biother Radiopharm; 2005 Feb; 20(1):11-5. PubMed ID: 15778574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous infusion interleukin-2 and famotidine in metastatic kidney cancer.
    Quan WD; Vinogradov M; Quan FM; Khan N; Liles DK; Walker PR
    Cancer Biother Radiopharm; 2006 Oct; 21(5):515-9. PubMed ID: 17105423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose continuous infusion plus pulse interleukin-2 and famotidine in metastatic kidney cancer.
    Quan W; Ramirez M; Taylor C; Vinogradov M; Quan F; Khan N
    Cancer Biother Radiopharm; 2005 Feb; 20(1):36-40. PubMed ID: 15778577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulse interleukin-2 with famotidine induces CD56+ lymphocytes in the peripheral blood of patients with metastatic melanoma or kidney cancer.
    Quan WD; Gagnon GA; Walker PR; Quan FM
    Cancer Biother Radiopharm; 2011 Feb; 26(1):65-7. PubMed ID: 21348776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated cycles with 72-hour continuous infusion interleukin-2 in kidney cancer and melanoma.
    Quan W; Brick W; Vinogradov M; Taylor WC; Khan N; Burgess R
    Cancer Biother Radiopharm; 2004 Jun; 19(3):350-4. PubMed ID: 15285881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.
    Bar MH; Sznol M; Atkins MB; Ciobanu N; Micetich KC; Boldt DH; Margolin KA; Aronson FR; Rayner AA; Hawkins MJ
    J Clin Oncol; 1990 Jul; 8(7):1138-47. PubMed ID: 2358835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.
    Parkinson DR; Abrams JS; Wiernik PH; Rayner AA; Margolin KA; Van Echo DA; Sznol M; Dutcher JP; Aronson FR; Doroshow JH
    J Clin Oncol; 1990 Oct; 8(10):1650-6. PubMed ID: 2213101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose cyclophosphamide and low-dose interleukin-2 for malignant melanoma.
    Mitchell MS; Kempf RA; Harel W; Shau H; Boswell WD; Lind S; Dean G; Moore J; Bradley EC
    Bull N Y Acad Med; 1989 Jan; 65(1):128-44. PubMed ID: 2532554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nursing care of patients receiving high-dose, continuous-infusion interleukin-2 with pulse dose and famotidine.
    Tyre CC; Quan W
    Clin J Oncol Nurs; 2007 Aug; 11(4):513-9. PubMed ID: 17723964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.